Voices From AdvaMed 2015: John Bishop On The Molecular Dx Environment
This article was originally published in The Gray Sheet
Executive Summary
In this "Gray Sheet" podcast from the AdvaMed meeting, John Bishop, CEO of Cepheid and chairman of AdvaMedDx, discusses the FDA and reimbursement outlook for molecular tests and his company's effort to broaden the reach of these traditionally complex diagnostic tools to the point of care.